Membranolytic agent associated with antibacterial agents |
|
|
|
Meropenem, ampicillin +
carbenicillin
|
Combination of 30 μg/mL carbenicillin with
2 μg/mL colistin or 200 μg/mL ampicillin with
2 μg/mL colistin
|
Clinical isolate Iso 03126 and Iso03368
|
[126]
|
Polymyxin B +
Meropenem
|
5, 10 and 15 μg/mL
|
Clinical isolate Acb-1, Acb-8 and Acb-2
|
[130]
|
Colistin + tobramycin
or rifampicin
|
10, 20 or 40 × MIC |
Reference ATCC 1797 |
[63] |
Colistin then amikacin or
vice versa
|
Colistin 5 × MIC
|
Clinical isolate C010
|
[132]
|
Colistin + econazole |
Econazole 10 µg/mL |
Reference ATCC 17978 and
clinical isolate CPC35 |
[133] |
Art-175 |
Tobramycin 30 × MIC |
Clinical isolate RUH875, LUH5875, NCTC
13423, and RUH134 |
[136] |
Persister eradication strategy |
|
|
|
Squalamine
Colistine
|
Squalamine 50 × MIC
Colistine 100 × MIC
|
Reference ATCC 17978
|
[36]
|
Carvacrol, Eugenol,
Thymol
|
Thymol 1 × MIC
Meropenem 100 × MIC.
|
Clinical isolate RPTC 8, 10, 11, 22, 31, 27
|
[125]
|